BOSTON, Mass. (

TheStreet

) -- A calendar of important, potentially stock-moving biotech events for February:

Feb 1:

Discovery Labs

(DSCO)

: Surfaxin regulatory update conference call.

Earnings:

Biogen Idec

(BIIB) - Get Report

,

Pfizer

(PFE) - Get Report

.

Feb. 2

Earnings:

Sangamo BioSciences

(SGMO) - Get Report

,

Viropharma

(VPHM)

.

Feb 3:

Alimera Sciences

(ALIM) - Get Report

: 36-month results from phase III study of Iluvien in diabetic macular edema.

Earnings:

Alkermes

(ALKS) - Get Report

,

GlaxoSmithKline

(GSK) - Get Report

,

Avanir Pharmaceuticals

(AVNR)

,

Merck

(MRK) - Get Report

,

Vertex Pharmaceuticals

(VRTX) - Get Report

,

Feb. 8:

Adeona Pharmaceuticals

( AEN) investor/analyst day.

Earnings:

Seattle Genetics

(SGEN) - Get Report

,

Rigel Pharmaceuticals

(RIGL) - Get Report

,

Teva

(TEVA) - Get Report

,

Feb. 9:

Earnings:

Sanofi-Aventis

(SNY) - Get Report

Feb. 10:

Earnings:

Alexion Pharmaceuticals

(ALXN) - Get Report

,

Cephalon

( CEPH),

Incyte Pharmaceuticals

(INCY) - Get Report

,

MannKind

(MNKD) - Get Report

,

Momenta Pharmaceuticals

(NNTA)

.

Feb 14-15:

BIO CEO & Investor Conference, New York City.

Feb 15:

Expiration of Sanofi-Aventis' $69-a-share tender offer for

Genzyme

( GENZ).

Feb. 16:

Earnings: Genzyme

Feb. 17:

Exelixis

(EXEL) - Get Report

: Presentation of updated cabozantinib (XL184) data in prostate cancer at ASCO GU symposium

Earnings:

Biomarin Pharmaceuticals

(BMRN) - Get Report

,

Acorda Therapeutics

(ACOR) - Get Report

Feb. 22:

Earnings:

Questcor Pharmaceuticals

(QCOR)

Feb 25:

Pfizer and

Protalix Therapeutics

(PLX) - Get Report

: FDA approval decision date for Uplyso in Gaucher's disease.

Other potential February events

Idenix Pharmaceuticals

(IDIX)

: FDA decision on lifting clinical hold on hepatitis C drugs IDX184 and IDX320.

Amylin Pharmaceuticals

( AMLN), Alkermes,

Eli Lilly

(LLY) - Get Report

: Start of a Bydureon Qt study.

Source: Company reports, BioMedTracker.com

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here:

Adam Feuerstein

.

>To follow the writer on Twitter, go to

http://twitter.com/adamfeuerstein

.

>To submit a news tip, send an email to:

tips@thestreet.com

.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.